Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BVX-1021 using a new batch of recombinant SARS-1 protein from the supplier that screened out the extraneous protein aggregate, has been synthesized using the purified SARS1 protein, OSU is now able to complete the neutralizing antibody studies.
Lead Product(s): BVX-1021,BVX-0320
Therapeutic Area: Infections and Infectious Diseases Product Name: BVX-1021
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Biovaxys
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022